FPR2 and scleroderma: In conclusion, the present study demonstrates that WKYMVm-induced Fpr2 activation relieves fibrosis by inhibiting fibroblast activation, macrophage infiltration and generation of M2 type macrophages, and inflammatory cytokine expression in BLM-induced scleroderma model.